• Company completes final development of Booze AI software 

• Booze AI predicts and estimates blood alcohol concentration using Speech and AI tools 

• Convenient software application for use on a Smartphone or Computer  

• Informational and educational tool with strong drink driving deterrence objective 

Vancouver, British Columbia – TheNewswire - May 26, 2025 – MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6), (“MindBio”), (the “Company”), a clinical-stage biopharma/biotechnology company dedicated to developing novel and effective mental health treatments, is pleased to announce the Company has completed development of the Booze AI software application and is preparing for first sales launch.  

Booze AI is the world’s first voice activated and AI powered blood alcohol estimator over a smartphone.  Booze AI users, after submitting baseline information, simply follow a few voice prompts and tasks on their smartphone, to receive an estimate of their Blood Alcohol Concentration (BAC).  The more the software learns about a user, the more meaningful the predictions and performance analysis becomes.  

This novel invention stems from a discovery in MindBio’s clinical trials that identified changes in speech patterns when patients ingested MB22001, (MindBio’s proprietary take-home microdose formulation of Lysergic Acid Diethylamide currently in multiple Phase 2B trials).  

The Company’s engineers analysed speech data collected from patients during treatment with MB22001. The engineers noted significant changes in the frequency domain of speech as drug concentrations in the blood increased.  They hypothesised that transforming the time domain speech signal using Fourier Transforms allowed the neural network to capture the three- dimensional relationships between the Mel spectrogram of the speaker (from the voice recording), and the substance being consumed and that this could be useful in drug and alcohol intoxication detection.

Booze AI has taken this concept to another level by developing a prediction tool and creation of a commercial software application, (App), on a smartphone or desktop with a microphone, using machine learning and artificial intelligence models to make blood alcohol concentration predictions.  The App analyses activity and voice data and compares vocal speech patterns, vocal power and amplitude of various frequencies when a user is sober vs when they are intoxicated.  The Booze AI proprietary prediction model (BAC-Regress 0.1) currently utilizes over 41 million points of data collected in human trials with 85% prediction accuracy, (in more than 20,000 tests within +-0.001BAC) when compared directly to the results of a commercial grade breathalyser.  Given the complexity of measuring BAC accurately at any moment in time, particularly as a person consumes alcohol (due to mouth alcohol residue and the transition time between alcohol entering the digestive system, transferring to the bloodstream and then degrading with metabolism), the BAC predictions by Booze AI provide remarkably informative and accurate results within an estimated range, with the outputs and communications to the consumer aimed at reducing harm during alcohol consumption.

Booze AI’s core philosophy is that alcohol should be enjoyed moderately AND there is zero safe amount of alcohol to drink then drive – even within legal statutory defined limits!  

The App not only predicts BAC, it also predicts and describes performance impairment whilst driving and visually presents the user with the potential catastrophic effects of even small amounts of alcohol consumed – even within allowable drink driving limits.  The application of the algorithm and development of an AI tool for alcohol intoxication prediction and BAC estimation is a powerful use case of this novel scientific discovery.

Booze AI is a convenient tool that can be used on every smartphone with the strong objective of education and drink driving deterrence.  The software has a broad commercial use case in drug and alcohol intoxication detection that the Company is exploring now the software development is complete.

“We are thrilled to complete the development of Booze AI, a transformative tool that reinforces our commitment to innovation,” said Justin Hanka, CEO of MindBio Therapeutics. “This world-first application has the potential to save lives by educating users about the risks of alcohol consumption, and we’re excited for its upcoming launch.”

MindBio invites stakeholders, partners, and the global community to join in supporting its vision for a brighter future in mental health.

  

1. Fourier Transform. In mathematics, the Fourier transform (FT) is an integral transform that takes a function as input then outputs another function that describes the extent to which various frequencies are present in the original function. The output of the transform is a complex-valued function of frequency. 

2. Mel Spectrogram. A visual representation of an audio signal’s frequency content over time, using the mel scale, which approximates how humans perceive sound. 

About MindBio Therapeutics
MindBio Therapeutics Corp. (CSE: MBIO; Frankfurt: WF6) is a clinical-stage biopharmaceutical company, focused on developing novel psychedelic-based medicines for mental health disorders. With a commitment to scientific rigor and patient accessibility, MindBio is pioneering the use of microdosing to provide safe, effective, and scalable treatments for conditions such as depression, anxiety, and other psychological challenges. The company’s mission is to improve global mental health outcomes through innovative, evidence-based treatment that is accessible and affordable.

 

For further information, please contact:

 

Justin Hanka, Chief Executive Officer

61 433140886

justin@mindbiotherapeutics.com

 

Media Inquiries

Kristina Spionjak

pr@hlthcommunications.com

  

Cautionary Note Concerning Forward-Looking Statements:

The press release contains "forward-looking statements" within the meaning of applicable securities laws. Forward-looking statements can be identified by words such as: "anticipate," "intend," "plan," "budget," "believe," "project," "estimate," "expect," "scheduled," "forecast," "strategy," "future," "likely," "may," "to be," "could," "would," "should," "will" and similar references to future periods or the negative or comparable terminology, as well as terms usually used in the future and conditional. Forward-looking statements are based on assumptions as of the date they are provided. However, there can be no assurance that such assumptions will reflect the actual outcome of such items or factors.

Additionally, there are known and unknown risk factors that could cause the Company's actual results and financial conditions to differ materially from those indicated in the forward-looking statements. Therefore, you should not rely on any of these forward-looking statements. Important risk factors that could cause actual results and financial conditions to differ materially from those indicated in the forward-looking statements, include among others: general economic, market and business conditions in Canada and Australia; market volatility; unforeseen delays in timelines for any of the transactions or events described in this press release.  All forward-looking information is qualified in its entirety by this cautionary statement.

The Company disclaims any obligation to revise or update any such forward-looking statement or to publicly announce the result of any revisions to any of the forward-looking information contained herein to reflect future results, events or developments, except as required by law.

Neither the Canadian Securities Exchange nor its Regulation Service Provider (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.